Segment Information (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

Schedule of Financial Information for the Company's Reportable Segments

The following tables present financial information for the Company's reportable segments for the periods indicated (in thousands):

	Three Months Ended September 30, 2025
	Finance Receivables		Pharmaceutical Development and Other		Holding Company and Other		Consolidated
Revenue	$	10,822	$	—	$	—	$	10,822
Other revenue	60		—		—		60
Benefit from credit losses	(931)		—		—		(931)
Loss on impairment of intangible assets	—		209		—		209
Interest expense	240		13		926		1,179
Pharmaceutical manufacturing, research and development expense	—		147		—		147
Loss on disposal of inventory	—		314		—		314
Depreciation and amortization expense	—		—		2		2
General and administrative expense	110		258		2,918		3,286
Other income expense, net	2,419		1,601		—		4,020
Income tax expense	—		—		1,916		1,916
Net income (loss)	13,882		660		(5,762)		8,780

	Three Months Ended September 30, 2024
	Finance Receivables		Pharmaceutical Development and Other		Holding Company and Other		Consolidated
Revenue	$	9,498	$	628	$	—	$	10,126
Other revenue	289		3		—		292
Provision for credit losses	1,385		—		—		1,385
Interest expense	230		2		907		1,139
Pharmaceutical manufacturing, research and development expense	—		585		—		585
Depreciation and amortization expense	—		214		20		234
General and administrative expense	85		722		2,186		2,993
Other income (expense), net	292		—		—		292
Income tax expense	—		—		906		906
Net income (loss)	8,379		(892)		(4,019)		3,468

	Nine Months Ended September 30, 2025
	Finance Receivables		Pharmaceutical Development and Other		Holding Company and Other		Consolidated
Revenue	$	30,077	$	2,153	$	—	$	32,230
Other revenue	420		116		—		536
Benefit from credit losses	(1,635)		—		—		(1,635)
Loss on impairment of intangible assets	—		209		—		209
Interest expense	713		18		2,733		3,464
Pharmaceutical manufacturing, research and development	—		1,550		—		1,550
Loss on disposal of inventory	—		314		—		314
Depreciation and amortization expense	—		—		40		40
General and administrative expense	236		1,553		7,617		9,406
Other income (expense), net	138		1,519		—		1,657
Income tax expense	—		—		4,220		4,220
Net income (loss)	31,321		144		(14,610)		16,855

	Nine Months Ended September 30, 2024
	Finance Receivables		Pharmaceutical Development and Other		Holding Company and Other		Consolidated
Revenue	$	30,519	$	1,711	$	—	$	32,230
Other revenue	392		3		—		395
Provision for credit losses	10,777		—		—		10,777
Loss on impairment of intangible assets	—		5,771		—		5,771
Interest expense	820		7		2,687		3,514
Pharmaceutical manufacturing, research and development expense	—		1,635		—		1,635
Depreciation and amortization expense	—		1,106		63		1,169
Change in fair value of acquisition-related contingent consideration	—		(4,900)		—		(4,900)
General and administrative expense	254		2,179		6,164		8,597
Other income (expense), net	4,135		—		(411)		3,724
Income tax expense	—		—		2,170		2,170
Net income (loss)	23,195		(4,084)		(11,495)		7,616

Schedule of Total Assets for the Company's Reportable Segments

The following table presents total assets for the Company's reportable segments for the periods indicated (in thousands):

	September 30, 2025		December 31, 2024
Total Assets
Finance receivables	$	266,580	$	299,248
Pharmaceutical development and other	—		7,786
Holdings Company and other	22,782		25,201
Total	$	289,362	$	332,235